GLPwatch
Targeting cardiometabolic risk in type 1 diabetes through incretin physiology.
Trends Endocrinol Metab · 2026
Last updated 2026-05-28People with type 1 diabetes face a higher risk of heart disease due to factors like high blood pressure, unhealthy cholesterol levels, and obesity. Their condition also involves issues with hormones that regulate blood sugar, such as GIP, GLP-1, and glucagon, which can further increase this risk. New medications like semaglutide (a GLP-1 drug) and tirzepatide (a combined GLP-1/GIP drug) may help address these hormone-related problems to reduce heart disease risk in this group.
AI summary of the abstract below.
| Journal | Trends Endocrinol Metab, 2026 |
|---|---|
| Citations | 1 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes, Cardiovascular Risk Reduction, Obesity |
Abstract
People living with type 1 diabetes have significantly increased cardiovascular risk compared with the general population. Traditional risk factors include hypertension, dyslipidaemia, and obesity. However, those with type 1 diabetes contend with treatment-induced insulin resistance and pancreatic and incretin hormone dysfunction, leading to dysglycaemia, which also impacts cardiovascular risk. Here, we highlight the underlying metabolic environment in type 1 diabetes with a focus on glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide 1 (GLP-1), and glucagon physiology. With the emergence of incretin-based therapies such as semaglutide (a GLP-1 receptor agonist) and tirzepatide (a combined GLP-1/GIP receptor agonist) targeting these receptor pathways, there is now potential to directly target metabolic deficits to address cardiometabolic risk in a type 1 diabetes population.
Verbatim abstract via PubMed 40610267 ↗